Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Copanlisib in Combination With Rituximab-Bendamustine in Patients With Relapsed-Refractory Diffuse Large B-cell Lymphoma: a Multicentric Phase II Trial

NCT04433182 is registered in ClinicalTrials.gov with Fondazione Italiana Linfomi - ETS as lead sponsor.

NCT NCT04433182
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04433182 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Copanlisib in Combination With Rituximab-Bendamustine in Patients With Relapsed-Refractory Diffuse Large B-cell Lymphoma: a Multicentric Phase II Trial
Lead sponsor
Fondazione Italiana Linfomi - ETS
Phase
Phase 2
Overall status
Terminated
Start date
August 18, 2020
Completion date
December 19, 2024
Enrollment
37 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b-cell lymphoma